Form 4: Altimmune Director Teri L. Lawver Acquires 69,800 Stock Options

Director Teri L. Lawver acquired 69,800 stock options in Altimmune, Inc. on February 24, 2025, according to a Form 4 filing with the SEC.

Summary

• Teri L. Lawver, a director of Altimmune, Inc., acquired 69,800 stock options on February 24, 2025.
• The exercise price of these options is $6.11.
• The options vest in 36 equal monthly installments starting from February 24, 2025, contingent upon continued service.
• The options expire on February 24, 2035.
• Following the transaction, Lawver directly owns 69,800 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option acquisition by a director. While insider confidence can be a positive signal, this is a routine grant.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are standard disclosures required by the SEC to ensure transparency in insider trading activities, providing investors with insights into the actions of company directors and officers.

Stakeholder Impact

• Shareholders may view the acquisition of stock options by a director as a sign of confidence in the company's future prospects.

Key Dates